RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib

Leukemia

Volumn 28, Issue 4, 2014, Pages 977-979

  Lilljebjorn H ^a   Agerstam H ^a   Orsmark Pietras, C ^a   Rissler, M ^a   Ehrencrona, H ^a   Nilsson, L ^b   Richter, J ^a,b   Fioretos, T ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; IMATINIB; MYOCYTE ENHANCER FACTOR 2; MYOCYTE ENHANCER FACTOR 2D; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PROGNOSIS; CELL GROWTH; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; CHRONIC MYELOID LEUKEMIA; DIMERIZATION; DNA BINDING; EXON; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE IDENTIFICATION; HUMAN; IN VITRO STUDY; LETTER; LEUKEMIA; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MACROPHAGE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; GENE FUSION; HUMANS; LEUKEMIA; MEF2 TRANSCRIPTION FACTORS; PIPERAZINES; PYRIMIDINES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SEQUENCE ANALYSIS, RNA;

EID: 84898466517     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.324     Document Type: Letter

References (15)

1. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations in cancer 2013; http://cgap.nci.nih.gov/Chromosomes/Mitelman.
2. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042. (Pubitemid 32267973)
3. Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-transretinoic acid). N Engl J Med 1991; 324: 1385-1393.
4. Pui C-H, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
5. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115-136.
6. Chase A, Ernst T, Fiebig A, Collins A, Grand F, Erben P et al. TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals. Haematologica 2010; 95: 20-26.
7. Iyer MK, Chinnaiyan AM, Maher CA. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 2011; 27: 2903-2904.
8. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
9. Toffalini F, Demoulin J-B. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 2010; 116: 2429-2437.
10. Mossadegh-Keller N, Sarrazin S, Kandalla PK, Espinosa L, Stanley ER, Nutt SL et al. M-CSF instructs myeloid lineage fate in single haematopoietic stem cells. Nature 2013; 497: 239-243.
11. Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci USA 1990; 87: 1377-1380.
12. Gu T, Mercher T, Tyner JW, Goss VL, Walters DK, Cornejo MG et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood 2007; 110: 323-333. (Pubitemid 47026850)
13. Chase A, Schultheis B, Kreil S, Baxter J, Hidalgo-Curtis C, Jones A et al. Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1. Leukemia 2008; 23: 358-364.
14. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
15. Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci USA 2005; 102: 16078-16083. (Pubitemid 41552870)